17-[2-(morpholin-4-yl)ethyl]amino-17-demethoxygeldanamycin

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 17-[2-(morpholin-4-yl)ethyl]amino-17-demethoxygeldanamycin
• 英文别名: 17-(2'-(4''-oxa-1''-azacyclohexyl-1H-)ethylamino)-17-demethoxygeldanamycin；[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-19-(2-morpholin-4-ylethylamino)-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
• 化学式: C₃₄H₅₀N₄O₉
• 分子量: 658.792
• InChiKey: OBFPHBBQQDLIMN-JEJDLLHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  47
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  179
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  N-(2-氨基乙基)吗啉 、 格尔德霉素 以 甲醇 、 氯仿 为溶剂， 反应 96.0h， 以61.2%的产率得到17-[2-(morpholin-4-yl)ethyl]amino-17-demethoxygeldanamycin
  参考文献：
  名称：

  A SET OF GELDANAMYCIN DERIVATIVES AND THEIR PREPARATION METHODS

  摘要：

  一组格尔丹霉素衍生物及其制备方法。包含所述化合物作为活性成分的药物组合物，用作抗病毒和抗肿瘤药剂。所述衍生物用于制造具有抗热休克蛋白90（Hsp 90）抑制作用的药剂，具有作为抗病毒和抗肿瘤药剂的用途。

  公开号：

  EP2253621A1

文献信息

• A SET OF GELDANAMYCIN DERIVATIVES AND THEIR PREPARATION METHODS
  申请人：Institute Of Medicinal Biotechnology, Chinese Academy of Medical Sciences

  公开号：EP2253621A1

  公开（公告）日：2010-11-24

  A set of geldanamycin derivatives and their preparation methods. Pharmaceutical compositions comprising the said compounds as an active ingredient which are used as antivirus and antitumor agents. The said derivatives are used in the manufacture of heat shock protein 90(Hsp 90) inhibiting agents which have the utility as antivirus and antitumor agents.

  一组格尔丹霉素衍生物及其制备方法。包含所述化合物作为活性成分的药物组合物，用作抗病毒和抗肿瘤药剂。所述衍生物用于制造具有抗热休克蛋白90（Hsp 90）抑制作用的药剂，具有作为抗病毒和抗肿瘤药剂的用途。
• Synthesis and biological activities of novel 17-aminogeldanamycin derivatives
  作者：Zong-Qiang Tian、Yaoquan Liu、Dan Zhang、Zhan Wang、Steven D. Dong、Christopher W. Carreras、Yiqing Zhou、Giulio Rastelli、Daniel V. Santi、David C. Myles

  DOI：10.1016/j.bmc.2004.07.053

  日期：2004.10

  Geldanamycin interferes with the action of heat shock protein 90 (Hsp90) by binding to the N-terminal ATP binding site and inhibiting an essential ATPase activity. In a program directed toward finding potent, water soluble inhibitors of Hsp90, we prepared a library of over sixty 17-alkylamino-17-demethoxygeldanamycin analogs, and compared their affinity for Hsp90, ability to inhibit growth of SKBr3 mammalian cells, and in selected cases, water solubility. Over 20 analogs showed cell growth inhibition potencies similar to that of 17-allylamino-17-demethoxygeldanamycin (17-AAG), the front-runner geldanamycin analog that is currently in multiple clinical trials. Many of these analogs showed water solubility properties that were desirable for formulation. One of the most potent and water-soluble analogs in the series was 17-(2-dimethylaminoethyl)amino-17-demethoxygeldanamycin (17-DMAG), which was independently prepared by the NCI and will soon enter clinical trials. Importantly, the binding affinity of these analogs to the molecular target Hsp90 does not correlate well with their cytotoxicity in SKBr3 cells. (C) 2004 Elsevier Ltd. All rights reserved.